<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25081">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01935414</url>
  </required_header>
  <id_info>
    <org_study_id>FKD-TEDS-001</org_study_id>
    <nct_id>NCT01935414</nct_id>
  </id_info>
  <brief_title>Geko Neuromuscular Stimulator vs Thromboembolism Deterrent Stockings (TEDS): DVT Prevention Study</brief_title>
  <official_title>A Multicentre Randomised Controlled Trial Comparing the Incidence of Asymptomatic and Symptomatic Deep Vein Thrombosis Between the gekoTM Device and Thromboembolism Deterrent Stockings in Patients Recovering From Total Hip Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Firstkind Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Firstkind Ltd</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study hypothesises that the geko™ device is more efficient than TEDS in preventing the
      formation of symptomatic/asymptomatic Deep Vein Thrombosis (DVTs), post-surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Presence of asymptomatic DVT assessed by Duplex Ultrasound</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>geko™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>geko™ use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TEDS stockings</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TEDS use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>geko™ post-surgery for 48hrs then 4hrs/day until discharge.</intervention_name>
    <arm_group_label>geko™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TEDS post-surgery for 48hrs then 4hrs/day until discharge.</intervention_name>
    <arm_group_label>TEDS stockings</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 years of age and over

          2. Free of significant abnormal findings as determined by medical history (specifically
             an absence of DVT or haematological disorders).

          3. Has not used any medications (prescribed or over-the-counter including herbal
             remedies) judged to be significant by the Principal Investigator during the ten (10)
             days preceding enrolment.

          4. Able to understand the Patient Information Sheet and willing to sign the written
             Informed Consent Form.

          5. Able and willing to follow the protocol requirements.

        Exclusion Criteria:

          1. Are requiring hip revision surgery

          2. History or signs of previous deep or superficial vein thrombosis/pulmonary embolism.

          3. Evidence of asymptomatic DVT by Duplex Ultrasound

          4. Peripheral arterial disease (ABPI &lt; 0.8), varicose veins or lower limb ulceration or
             ischemia.

          5. Significant varicose veins, phlebitis or lower limb ulceration or ischemia. CEAP
             Grade 4-6. See Appendix  2

          6. Recent surgery within the last 3 months (such as abdominal, gynaecological, hip or
             knee replacement).

          7. Recent trauma to lower limb.

          8. Chronic Obesity (BMI Index &gt;40kg/m2).

          9. Pregnancy.

         10. Significant history of following diseases I. Cardiovascular: Recent MI (&lt; 6 months)
             II. Percutaneous Coronary Intervention (PCI) with stent (&lt; 3 months for Bare Metal
             Stent (BMS) and &lt; 12 months for Drug Eluding Stent (DES) III. Moderate to severe CCF,
             uncontrolled AF IV. Neurological: Stroke, Hemiplegia/Paraplegia, Myopathies V.
             Significant dermatological conditions affecting lower limbs resulting in broken or
             inflamed skin particularly at the site where the device is to be fitted.

             VI. Clinically significant haematological conditions i.e. coagulation disorders,
             sickle cell disease VII. Psychiatric disorders

         11. On LMWH/Heparin (Prophylactic/therapeutic doses) or Warfarin or warfarin stopped
             recently and replaced by LMWH/ Heparin

         12. Long term steroid with dermatological changes

         13. A pulse rate of less than 40 beats/minute

         14. A sitting systolic blood pressure &gt;180 and &lt;100 mmHg and/or a sitting diastolic
             pressure of &gt;100 mmHg.

         15. Any significant illness during the four (4) weeks preceding the hip replacement
             surgery.

         16. Participation in any clinical study during the eight (8) weeks preceding the
             screening period
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthew Womack, PhD</last_name>
    <phone>+44(0) 7456427910</phone>
    <email>matthew.womack@firstkindmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BMI The Harbour Hospital</name>
      <address>
        <city>Poole</city>
        <state>Dorset</state>
        <zip>BH15 2BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.gekodevices.com/en-uk/</url>
    <description>Company website</description>
  </link>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 30, 2013</lastchanged_date>
  <firstreceived_date>August 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
